Table S4 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Year: 2023
Type: other
Abstract: Table S4 shows a comparison of central cobas tissue and baseline cobas plasma test results for EGFR-TKI sensitizing mutations (All screened patients)
Authors: Jhanelle E. Gray, Isamu Okamoto, Virote Sriuranpong, Johan Vansteenkiste, Fumio Imamura, Jong Seok Lee, Yong-Kek Pang, Manuel Cobo, Kazuo Kasahara, Ying Cheng, Naoyuki Nogami, Eun Kyung Cho, Wu Chou Su, Guili Zhang, Xiangning Huang, Xiaocheng Li-Sucholeiki, Brian Lentrichia, Simon Dearden, Suzanne Jenkins, Matilde Saggese, Yuri Rukazenkov, Suresh S. Ramalingam
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361934830